AR126900A1 - Polipéptidos de coronavirus modificados genéticamente, polinucleótidos, vectores y células huésped, y composiciones relacionadas - Google Patents
Polipéptidos de coronavirus modificados genéticamente, polinucleótidos, vectores y células huésped, y composiciones relacionadasInfo
- Publication number
- AR126900A1 AR126900A1 ARP220102318A ARP220102318A AR126900A1 AR 126900 A1 AR126900 A1 AR 126900A1 AR P220102318 A ARP220102318 A AR P220102318A AR P220102318 A ARP220102318 A AR P220102318A AR 126900 A1 AR126900 A1 AR 126900A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- polypeptide
- rbd
- amino acid
- acid sequence
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 21
- 229920001184 polypeptide Polymers 0.000 title abstract 20
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 20
- 108091033319 polynucleotide Proteins 0.000 title abstract 5
- 102000040430 polynucleotide Human genes 0.000 title abstract 5
- 239000002157 polynucleotide Substances 0.000 title abstract 5
- 241000711573 Coronaviridae Species 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000013598 vector Substances 0.000 title abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 7
- 102000037865 fusion proteins Human genes 0.000 abstract 7
- 108020001507 fusion proteins Proteins 0.000 abstract 7
- 101100377809 Arabidopsis thaliana ABC1K3 gene Proteins 0.000 abstract 3
- 241001678559 COVID-19 virus Species 0.000 abstract 3
- 101100135806 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PCP1 gene Proteins 0.000 abstract 3
- 241000008904 Betacoronavirus Species 0.000 abstract 2
- 208000001528 Coronaviridae Infections Diseases 0.000 abstract 2
- 108700023317 Coronavirus Receptors Proteins 0.000 abstract 2
- 101150062156 RBD2 gene Proteins 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 241001678561 Sarbecovirus Species 0.000 abstract 1
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4634—Antigenic peptides; polypeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
- C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Se proporcionan aquí polipéptidos de coronavirus de ingeniería, polinucleótidos que codifican los polipéptidos, vectores y células huésped que comprenden los polinucleótidos y/o expresan los polipéptidos, y composiciones relacionadas. Las formas de realización divulgadas incluyen, por ejemplo, ectodominios de espiga diseñados, dominios de unión a receptores monoméricos (RBD), RBD diseñados y proteínas de fusión que comprenden uno o más de los anteriores. Reivindicación 1: Una proteína de fusión que comprende un primer polipéptido de dominio de unión al receptor (RBD) de coronavirus unido a un segundo polipéptido RBD de coronavirus, en el que, opcionalmente, el primer y/o el segundo polipéptido RBD son de un betacoronavirus, y en el que, además, opcionalmente, el primer y el segundo polipéptido RBD son de diferentes betacoronavirus. Reivindicación 40: Un polipéptido aislado que comprende: (i) SEQ ID Nº 218; (ii) SEQ ID Nº 218 sin la SEQ ID Nº 706; (iii) SEQ ID Nº 712; (iv) SEQ ID Nº 712 sin SEQ ID Nº 706; (v) SEQ ID Nº 713; (vi) SEQ ID Nº 713 sin la SEQ ID Nº 706; (vii) SEQ ID Nº 714; (viii) SEQ ID Nº 714 sin la SEQ ID Nº 706; (ix) SEQ ID Nº 715; (x) SEQ ID Nº 715 sin la SEQ ID Nº 706; (xi) SEQ ID Nº 716; (xii) SEQ ID Nº 716 sin la SEQ ID Nº 706; (xiii) SEQ ID Nº 717; (xiv) SEQ ID Nº 717 sin la SEQ ID Nº 706; (xv) SEQ ID Nº 738; (xvi) SEQ ID Nº 739; (xvii) SEQ ID Nº 740; (xviii) SEQ ID Nº 741; (xix) SEQ ID Nº 742; o (xx) SEQ ID Nº 743. Reivindicación 42: Una proteína de fusión que comprende un polipéptido del dominio de unión al receptor (RBD) del coronavirus y uno o ambos de (i) y (ii), (i) una o más etiquetas peptídicas; (ii) uno o más polipéptidos de tallo-hélice, en los que, opcionalmente, el uno o más polipéptidos de tallo-hélice comprenden o consisten en la secuencia de aminoácidos PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID Nº 701). Reivindicación 57: Un polipéptido aislado que comprende una estructura RBD1 - L1 - RBD2 - L2 - RBD3 - L3 - RBD4 - L4 - RBD5 en donde RBD1, RBD2, RBD3, RBD4 y RBD5 son cada uno un polipéptido RBD diferente seleccionado del grupo que consiste en: variante Beta del SARS-CoV-2; variante Omicron del SARS-CoV-2; variante Delta del SARS-CoV-2; PANG/GX; MP789; RaTG13; y RsSHC014, en donde RBD1 es el polipéptido RBD N-terminal de la proteína de fusión y/o RBD5 es el polipéptido RBD C-terminal de la proteína de fusión, y en donde L1, L2, L3 y L4 son cada uno un enlazador. Reivindicación 63: Un polipéptido aislado que comprende o consiste en la secuencia de aminoácidos de cualquiera de las SEQ ID Nº 701, 4 - 19, 46 y 57 - 59. Reivindicación 64: Un polipéptido aislado que comprende o consiste en la secuencia de aminoácidos de SEQ ID Nº 701, la secuencia de aminoácidos de SEQ ID Nº 14, la secuencia de aminoácidos de SEQ ID Nº 15, la secuencia de aminoácidos de SEQ ID Nº 16, o la secuencia de aminoácidos de SEQ ID Nº 17. Reivindicación 65: Un polinucleótido aislado que codifica la proteína de fusión de acuerdo con cualquiera de las reivindicaciones 1 - 39 y 42 - 56, o el polipéptido de acuerdo con cualquiera de las reivindicaciones 40, 41 y 57 - 64. Reivindicación 72: Un método para tratar, o para inducir una respuesta inmunitaria contra una infección por coronavirus en un sujeto, el método comprende administrar al sujeto una cantidad eficaz de: la proteína de fusión de acuerdo con cualquiera de las reivindicaciones 1 - 39 y 42 - 56; el polipéptido de acuerdo con cualquiera de las reivindicaciones 40, 41 y 57 - 64; el polinucleótido de acuerdo con cualquiera de las reivindicaciones 65 - 67; el vector de acuerdo con la reivindicación 68; la célula huésped de acuerdo con la reivindicación 69; o la composición de acuerdo con la reivindicación 70 o 71, en donde, opcionalmente, la infección por coronavirus comprende una infección por sarbecovirus.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163238078P | 2021-08-27 | 2021-08-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126900A1 true AR126900A1 (es) | 2023-11-29 |
Family
ID=83457424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220102318A AR126900A1 (es) | 2021-08-27 | 2022-08-26 | Polipéptidos de coronavirus modificados genéticamente, polinucleótidos, vectores y células huésped, y composiciones relacionadas |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR126900A1 (es) |
| TW (1) | TW202315895A (es) |
| WO (1) | WO2023028603A2 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023534923A (ja) | 2020-07-06 | 2023-08-15 | フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー | ＳＡＲＳ－ＣｏＶ－２を標的にする抗原結合分子 |
| EP4204446A1 (en) | 2020-08-26 | 2023-07-05 | Flagship Pioneering Innovations VI, LLC | Antigen binding molecules targeting sars-cov-2 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| AU782626B2 (en) | 1999-10-04 | 2005-08-18 | Medicago Inc. | Method for regulating transcription of foreign genes |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| DE10113776B4 (de) | 2001-03-21 | 2012-08-09 | "Iba Gmbh" | Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins |
| EP1633775A2 (en) * | 2003-06-13 | 2006-03-15 | Crucell Holland B.V. | Antigenic peptides of sars coronavirus and uses thereof |
| US8119772B2 (en) | 2006-09-29 | 2012-02-21 | California Institute Of Technology | MART-1 T cell receptors |
-
2022
- 2022-08-26 TW TW111132369A patent/TW202315895A/zh unknown
- 2022-08-26 AR ARP220102318A patent/AR126900A1/es unknown
- 2022-08-26 WO PCT/US2022/075541 patent/WO2023028603A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202315895A (zh) | 2023-04-16 |
| WO2023028603A2 (en) | 2023-03-02 |
| WO2023028603A3 (en) | 2023-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR126900A1 (es) | Polipéptidos de coronavirus modificados genéticamente, polinucleótidos, vectores y células huésped, y composiciones relacionadas | |
| Shirayoshi et al. | Cadherin cell adhesion molecules with distinct binding specificities share a common structure. | |
| Reinhard et al. | VASP interaction with vinculin: a recurring theme of interactions with proline‐rich motifs | |
| Grand et al. | The amino acid sequence of the troponin C-like protein (modulator protein) from bovine uterus | |
| Kiyatkin et al. | Cloning and structure of cDNA encoding α‐latrotoxin from black widow spider venom | |
| Marquardt et al. | Complete amino acid sequence of human transforming growth factor type beta 2. | |
| Gospodarowicz | [9] Isolation and characterization of acidic and basic fibroblast growth factor | |
| Algrain et al. | Ezrin contains cytoskeleton and membrane binding domains accounting for its proposed role as a membrane-cytoskeletal linker. | |
| Zani et al. | The mechanism of binding of exogenous DNA to sperm cells: factors controlling the DNA uptake | |
| Trainin et al. | Thymic hormones: inducers and | |
| Hodel et al. | In chromaffin cells, the mammalian Sec1p homologue is a syntaxin 1A-binding protein associated with chromaffin granules. | |
| Bulinski et al. | Peptide antibody specific for the amino terminus of skeletal muscle alpha-actin. | |
| CA2190371A1 (en) | Receptor for oncostatin m | |
| Jander et al. | A collagen-like glycoprotein of the extracellular matrix is the undegraded form of type VI collagen | |
| Baglia et al. | Nuclear ribonucleoprotein release and nucleoside triphosphatase activity are inhibited by antibodies directed against one nuclear matrix glycoprotein. | |
| ATE146219T1 (de) | Polypeptid | |
| Graham et al. | Complete amino acid sequence of soybean leaf P21: similarity to the thaumatin-like polypeptides | |
| Aubert-Foucher et al. | Purification and characterization of native type XIV collagen. | |
| KR960701899A (ko) | 인자 viii:c활성을 갖는 단백질 복합체 및 그의 제조 | |
| Lethias et al. | Flexilin: A new extracellular maxtrix glycoprotein localized on collagen fibrils | |
| Engström et al. | Amino acid and cDNA sequences of lysozyme from Hyalophora cecropia | |
| Fresco et al. | Leucine periodicity of U2 small nuclear ribonucleoprotein particle (snRNP) A'protein is implicated in snRNP assembly via protein-protein interactions | |
| Pottinger et al. | The identification and purification of the heterotrimeric GTP-binding protein from squid (Loligo forbesi) photoreceptors. | |
| Valentine-Braun et al. | Epidermal growth factor (urogastrone)-mediated phosphorylation of a 35-kDa substrate in human placental membranes: relationship to the beta subunit of the guanine nucleotide regulatory complex. | |
| DK0446315T3 (da) | Fremgangsmåde til fremstilling af PAI-2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |